NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 44m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTAMINE (Iofetamine Hydrochloride I-123) is a radiopharmaceutical injectable used for diagnostic imaging, specifically for brain perfusion studies via single-photon emission computed tomography (SPECT). The drug delivers I-123 radiolabeled iofetamine to visualize cerebral blood flow, aiding in the diagnosis of stroke, dementia, and other neurological conditions.
LOE Approaching
As LOE approaches, the brand team is likely consolidating, with focus shifting from growth initiatives to lifecycle management and cost containment strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SPECTAMINE represents a mature, stable diagnostic product with limited growth trajectory; career opportunities center on efficient commercial operations, regulatory maintenance, and lifecycle management. This role suits professionals seeking stability in a specialized radiopharmaceutical niche rather than high-growth brand development.
Product ManagerRegional Sales Manager
Worked on SPECTAMINE at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.